Organization | Dutch Arthritis Association

Dutch Arthritis Association Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Amsterdam Netherlands

Organization Overview

First Clinical Trial

2000

NCT00391924

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Dutch Arthritis Association

Active Ingredients

Drugs in Phase 4 Trials (3)

azathioprine (imuran) (1 trial)

etanercept (enbrel) (1 trial)

lidocaine (xylocaine) (1 trial)

Drugs in Phase 3 Trials (1)

rituximab (rituxan) (2 trials)

Drugs in Phase 2 Trials (2)

autologous mature tolerogenic monocyte-derived dendritic cells loaded with the b29 peptide of hsp70 (1 trial)

dehydroepiandrosterone (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Arthritis (Phase 4)

Arthritis, Juvenile (Phase 4)

Lupus Erythematosus, Systemic (Phase 2)

Sjogren's Syndrome (Phase 2)

Syndrome (Phase 2)

Tendinopathy (Phase 4)

Vasculitis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 7
# of Trial APIs: 6